Biopharma | May 13, 2026
Eli Lilly launches Lormalzi for early Alzheimer’s treatment in India
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The hospital said the new centre will improve access to specialised interventions such as Deep Brain Stimulation
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
New study presents a human-relevant stress model for assessing potential therapeutics
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Subscribe To Our Newsletter & Stay Updated
